An ω-3 endocannabinoid epoxide and CB receptor agonist
Related Products
Parent Compound(s)
10007534Docosahexaenoyl Ethanolamide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

(±)19(20)-EDP Ethanolamide

Item No. 25917

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
18-(3-ethyl-2-oxiranyl)-N-(2-hydroxyethyl)-4Z,7Z,10Z,13Z,16Z-octadecapentaenamide
CAS Number
2123485-34-5
Synonyms
  • 19,20-DHEA epoxide
  • 19,20-epoxy Docosapentaenoic Acid Ethanolamide
  • 19,20-EDP-EA
  • 19,20-EDP epoxide
Molecular Formula
C24H37NO3
Formula Weight
387.6
Purity
≥98%
Formulation (Request formulation change)
A 100 µg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
DMF: 50 mg/mlDMSO: 50 mg/mlEthanol: 50 mg/mlEthanol:PBS(pH 7.2) (1:1): 0.5 mg/ml
SMILES
CCC1C(O1)C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(NCCO)=O
InChi Code
InChI=1S/C24H37NO3/c1-2-22-23(28-22)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-19-24(27)25-20-21-26/h3-4,7-10,13-16,22-23,26H,2,5-6,11-12,17-21H2,1H3,(H,25,27)/b4-3-,9-7-,10-8-,15-13-,16-14-
InChi Key
HQRHKQCFLLFLJV-MBYQGORISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 µg

    $46

    Add

    50 µg

    $86

    Add

    100 µg

    $160

    Add

    500 µg

    $707

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    (±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide (DHEA; Item No. 10007534) by cytochrome P450 (CYP) epoxygenases.1,2 (±)19(20)-EDP ethanolamide (25 µM) reduces the viability of 143B metastatic osteosarcoma cells.2 It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 µM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 µM. It also decreases nitrite production when used at a concentration of 7.5 µM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 (Item No. 10006974) and the PPARγ antagonist GW 9662 (Item No. 70785). (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 µM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel™ assay.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. McDougle, D.R., Watson, J.E., Abdeen, A.A., et al. Anti-inflammatory ω-3 endocannabinoid epoxides. Proc. Natl. Acad. Sci. USA 114(30), E6034-E6043 (2017).

    2. Roy, J., Watson, J.E., Hong, I.S., et al. Antitumorigenic properties of omega-3 endocannabinoid epoxides. J. Med. Chem. 61(13), 5569-5579 (2018).